Growing Prevalence of Autistic & Related Disorders Has Enhanced the Autism Disorder & Treatment Market Growth Over the Forecast Period, 2017–2023

Pune, India, April 2018 /MRFR Press Release/- Market Research Future has Published a Cooked research report on the Global Autism Disorder & Treatment Market.

Market Highlights

Growing burden of autism in western countries has majorly contributed to the growth of the market and is likely to increase due to growing number of cases of autism around the globe in the coming years which will also boost the market growth during the forecast period. Environmental and genetic factors are major factors which have majorly increased the prevalence of autism disorder, and it is expected to increase in the coming decade due to various factors such as poor nutritional conditions of children and adolescents, increasing environmental toxins and increasing prenatal and perinatal maternal stress. According to a recent epidemiological study, it has been observed that around 87% of the ASD cases are from Europe, Japan, and North America, while only 10% of the world’s children live in these countries. Moreover, the Centers for Disease Control's (CDC) Autism and Developmental Disabilities Monitoring (ADDM) society stated that approximately 1 in 68 children in the United States was identified with an Autism Spectrum Disorder (ASD) in 2016.

Taste the market data and market information presented through more than 98 market data tables and 14 figures spread over 108 pages of the project report. Avail the in-depth table of content TOC & market synopsis on the “Autism Disorder & Treatment Market Research Report–Global forecast till 2023.”

Access Report Details @ https://www.marketresearchfuture.com/reports/autism-disorder-and-treatment-market-1605

Major Players in the Autism Disorder & Treatment Market

Some of the key players in this market are Pfizer Inc., Eli Lilly and Company, Allergan, Merck & CO Inc., Teva Pharmaceutical Industries Ltd., Consern Pharma Private Limited, Novartis AG, Johnson & Johnson Services, Inc. Bristol-Myers Squibb and Otsuka Holdings Co., Ltd., Coronis Partners Ltd., Curemark LLC, Heptares Therapeutics Limited, Intra-Cellular Therapies Inc., and Saniona AB.

The global autism disorder & treatment market is segmented into four major regions including Americas, Europe, Asia Pacific and the Middle East & Africa.

The global autism disorder and treatment market has been identified as one of the rapidly growing industries, owing to rising prevalence of autism and Pervasive Developmental Disorder (PDD) and raising awareness about autism among the patient population. Autism disorder and treatment is observed as one of the significantly growing markets in the healthcare sector because of initiatives by the government of various nations and expected approvals of various off-label treatment therapies by the Food and Drug Association (FDA). With the upsurge in the market, there are some hindrances faced by the market such as a weak pipeline of drugs for autism disorder and unknown etiology and pathophysiology of ASD.  

Segmentation

The global autism disorder & treatment market is segmented by type, treatment type, and drugs. On the basis of type, it is segmented into Asperger Syndrome, Pervasive Developmental Disorder, others. On the basis of treatment type, it is segmented into ABA (applied behavioral analysis), hyperbaric oxygen therapy, chelation therapy, oxytocin therapy and others. On the basis of drugs, it is segmented into SSRIs, anti-convulsant, stimulants, anti-psychotic. Anti-psychotics are further segmented into Abilify (aripiprazole) and Risperidone.